Related references
Note: Only part of the references are listed.PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non-small-cell lung cancer
Yu Jiang et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Comparison of Biomarker Assays for EGFR: Implications for Precision Medicine in Patients with Glioblastoma
Andrew B. Lassman et al.
CLINICAL CANCER RESEARCH (2019)
PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers
Patrick G. Pilie et al.
CLINICAL CANCER RESEARCH (2019)
Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer
Triparna Sen et al.
CANCER DISCOVERY (2019)
PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
Constantia Pantelidou et al.
CANCER DISCOVERY (2019)
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
R. L. Coleman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
LBA4_PRNivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 part 1 final analysis
S Peters et al.
ANNALS OF ONCOLOGY (2019)
Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies
Leonard J. Appleman et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study
Taofeek K. Owonikoko et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation
Tathiane M. Malta et al.
CELL (2018)
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
M. Catherine Pietanza et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer
Mark A. Socinski et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas
Theo A. Knijnenburg et al.
CELL REPORTS (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors
Andrea E. Wahner Hendrickson et al.
CLINICAL CANCER RESEARCH (2018)
Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study
H. S. Han et al.
ANNALS OF ONCOLOGY (2018)
Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non-Small Cell Lung Cancer
Suresh S. Ramalingam et al.
CLINICAL CANCER RESEARCH (2017)
Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung Cancer
Martin Reck et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review
Robert Brody et al.
LUNG CANCER (2017)
Update on the Treatment of Metastatic Squamous non-Small Cell Lung Cancer in new era of Personalized Medicine
Sara Victoria Soldera et al.
FRONTIERS IN ONCOLOGY (2017)
Validation of the Lung Subtyping Panel in Multiple Fresh-Frozen and Formalin-Fixed, Paraffin-Embedded Lung Tumor Gene Expression Data Sets
Hawazin Faruki et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2016)
Clinicopathologic Features of Advanced Squamous NSCLC
Mark A. Socinski et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study
Robert L. Coleman et al.
GYNECOLOGIC ONCOLOGY (2015)
Disparities in Treatment of Patients with Inoperable Stage I Non-Small Cell Lung Cancer: A Population-Based Analysis
Matthew Koshy et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer
Cristina Chamizo et al.
BMC PULMONARY MEDICINE (2015)
Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer
Taofeek K. Owonikoko et al.
CANCER MEDICINE (2014)
Prediction of Lung Cancer Histological Types by RT-qPCR Gene Expression in FFPE Specimens
Matthew D. Wilkerson et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2013)
Artd1/Parp1 Regulates Reprogramming by Transcriptional Regulation of Fgf4 Via Sox2 ADP-Ribosylation
Fabienne A. Weber et al.
STEM CELLS (2013)
Comprehensive genomic characterization of squamous cell lung cancers
Peter S. Hammerman et al.
NATURE (2012)
SRY (sex determining region Y)-box2 (Sox2)/poly ADP-ribose polymerase 1 (Parp1) complexes regulate pluripotency
Yi-Shin Lai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Estimation of the effects of smoking and DNA repair capacity on coefficients of a carcinogenesis model for lung cancer
Li Deng et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
ABT-888, an orallyactive poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models
Cherrie K. Donawho et al.
CLINICAL CANCER RESEARCH (2007)
Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase
Paolo Ceppi et al.
CANCER (2006)
In silico characterization of the family of PARP-like poly(ADP-ribosyl) transferases (pARTs) -: art. no. 139
H Otto et al.
BMC GENOMICS (2005)
DNA repair activity for oxidative damage and risk of lung cancer
T Paz-Elizur et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Share Paper
